---
title: "Gyre Therapeutics, Inc. (GYRE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GYRE.US.md"
symbol: "GYRE.US"
name: "Gyre Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T16:07:29.670Z"
locales:
  - [en](https://longbridge.com/en/quote/GYRE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GYRE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GYRE.US.md)
---

# Gyre Therapeutics, Inc. (GYRE.US)

## Company Overview

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.gyretx.com](https://www.gyretx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 38 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 16.30% |  |
| Net Profit YoY | -187.74% |  |
| P/B Ratio | 5.65 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 571988363.18 |  |
| Revenue | 117049000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.51% | D |
| Profit Margin | -5.44% | D |
| Gross Margin | 94.55% | A |
| Revenue YoY | 16.30% | B |
| Net Profit YoY | -187.74% | E |
| Total Assets YoY | 24.83% | A |
| Net Assets YoY | 31.33% | A |
| Cash Flow Margin | -67.89% | E |
| OCF YoY | 16.30% | B |
| Turnover | 0.80 | B |
| Gearing Ratio | 15.45% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Gyre Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "16.30%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-187.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.65",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "571988363.18",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "117049000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.51%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-5.44%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "94.55%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "16.30%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-187.74%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "24.83%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "31.33%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-67.89%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "16.30%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.80",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.45%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -89.91 | 544/386 | 161.15 | 112.20 | 100.90 |
| PB | 5.65 | 343/386 | 9.53 | 7.26 | 6.68 |
| PS (TTM) | 4.89 | 106/386 | 7.12 | 6.67 | 6.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.39 |
| Highest Target | 20.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GYRE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GYRE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GYRE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GYRE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**